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Summary 
Recent studies suggest that some T and B lymphocyte cell lines bind to the integrin lymphocyte 
function-associated molecule 1 (LFA-1) chiefly through a pathway independent of its two known 
counter-receptors, intercellular adhesion molecules (ICAMs)-I and -2. A monoclonal antibody 
(mAb) was raised that, in combination with blocking mAb to ICAM-1 and ICAM-2, can completely 
inhibit binding of these cell lines to purified LFA-1. This third ligand, designated ICAM-3 based 
on its functional relatedness to ICAM-1 and -2, is a highly glycosylated protein of 124,000 Mr. 
It is well expressed on all leukocytes and absent from endothelial cells.  In assays of adhesion 
of resting lymphocytes to purified LFA-1, ICAM-3 is by far the most functionally important 
ICAM,  implying an important role for ICAM-3 in the generation of immune responses. 
Lymphocyte function-associated molecule 1 (LFA-1)  1 is an 
integrin that mediates a wide range of leukocyte interactions 
with other cells in immune and inflammatory responses (1, 
2). Two homologous immunoglobulin family counter-recep- 
tors for LFA-1 have been discovered: the inducible intercel- 
lular adhesion molecule I (ICAM-1) (3-5) and constitutively 
expressed ICAM-2 (6). Development of a mAb to ICAM-2 
allowed  several  previously LFA-l-dependent,  ICAM-I-in- 
dependent phenomena to be analyzed and suggested that a 
third ligand for LFA-1 existed (7). Binding of several cell types 
such as epithelial and endothelial cells to purified LFA-1 could 
be completely blocked with a combination of ICAM-1 and 
ICAM-2 mAb, whereas an ICAM-I-, ICAM-2-independent 
pathway of adhesion to LFA-1 existed on many lymphoid cell 
lines,  including the T  call lymphoma call line, SKW3 (7). 
We now report on the production and characterization of 
a mAb, CBR-IC3/1, that, in conjunction with anti-ICAM-1 
and anti-ICAM-2 mAbs, can completely inhibit adhesion of 
a variety of call lines to purified LFA-1. Due to its functional 
role as a LFA-1 ligand, we have termed this novel molecule 
ICAM-3. The biochemical characteristics and cell distribu- 
tion of ICAM-3 are distinct from those of either ICAM-1 
or ICAM-2. 
: Abbreviations used in this paper: LFA-1, lymphocyte  function-associated 
molecule 1; ICAM, intercellular  adhesion molecule. 
Materials and Methods 
MonoclonalAntibodies.  The following previously described rou- 
tine mAbs to human antigens were used: TS2/16 (anti-CD29, IgG1) 
(8), RR1/1 (anti-ICAM-1, IgG1) (4), CBK-IC2/1 (anti-ICAM-2, 
IgG2a) (7), CBR-IC2/2 (anti-ICAM-2, IgG2a) (7), and X63 (non- 
binding  antibody,  IgG1). All mAbs  were titered  and  used  at 
saturating concentrations (1:200 dilution of mAb ascites), 
Cell Culture.  The maintenance and growth conditions of the 
routine myeloma P3X63AgS.653 and hybridomas have been de- 
scribed (7). The human lymphoid cell lines were grown in RPMI 
1640 supplemented  with 10% FCS, 5 mM glutamine, and 50 #g/m1 
gentamicin at 370C and in the presence of 5% CO2. 
PBMC and neutrophils were obtained as described (7). Lym- 
phocytes and monocytes were separated  by cytometric anal)  sis using 
forward and perpendicular light  scatter, and their identity was 
confirmed by monocyte- and T cell-specific  mAbs. Resting T ceils 
were isolated from whole blood by plastic adherence  and nylon wool 
filtration and were 91% CD2 +, while PHA blasts were generated 
by culturing the cells for 3 d in the presence of 10 Izg/ml PHA 
(Sigma Chemical Co., St. Louis, MO). 
Development oflCAM-3 Hybn'doma.  SKW3 cells were used to 
immunize 3-12-wk-old BALB/c  female  mice (Charles River Labora- 
tories, Wilmington, MA). Immunizations  (10s-106 calls per in- 
traperitoneal immunization)  were given three times at 3-wk in- 
tervals. 3 d before fusion with the murine mydoma  P3X63Ag8.653, 
the mice were injected  both intraperitoneally  and intravenously  with 
5  x  10  s SKW3 cells. The protocol for fusion and subsequent 
maintenance of hybridomas was described previously (9). 600 hy- 
bridomas were screened for the ability to inhibit SKW3 binding 
to purified LFA-1 in the presence of mAb to ICAM-1 and ICAM- 
2. On this basis one mAb, CBK-IC3/1,  was selected for further 
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typed by ELISA using affinity-purified  antibodies to mouse immu- 
noglobulins (Zymed Immunochemicals, San Francisco,  CA). 
Flow Cytometric  Analysis.  Immunofluorescence flow cytometry 
was performed on an EPICS V  analyzer (Coulter Diagnostics, 
Hialeah, FL) after staining cells with mAb-containing supernatants 
followed by FITC-conjugated anti-mouse antibody (Zymed Immu- 
nochemicals) as described (7). Since both primary and secondary 
mAbs were used at saturating concentrations, membrane antigen 
expression could be quantitated as a measure of mean fluorescence 
intensity (10). 
Su~ce Iodination.  Surface labeling of cells with 125I was per- 
formed as described using Iodogen (Pierce Chemical Co., Rock- 
ford, IL) (11). Triton X-100 (1%) lysates were cleared with bovine 
IgG-coupled-Sepharose  and then incubated with appropriate mAb- 
bound Sepharose for 2 h. Beads were washed and heated at 100~ 
in sample buffer containing 50 mM Tris, 1% SDS, and 1% 2-ME 
or 20 mM iodoacetamide. Samples were subjected to SDS 7% PAGE 
(12) and autoradiography with enhancing screens. Treatment of 
samples with N-Glycanase (Genzyme, Boston, MA) was as previ- 
ously described (13); samples were incubated with 10 U/ml N-Gly- 
canase for 18 h  at 37~ 
Purification of LFA-1.  LFA-1  was purified from JY lysates on 
TS2/4-Sepharose as described previously (14). The LFA-1 bound 
to TS2/4-Sepharose was eluted with 50 mM triethylamine (pH 
11.5),  150 mM NaC1,  2 mM MgCI2,  and 1% octyl 3-D-gluco- 
Fyranoside. Samples were neutralized and stored frozen at  -70~ 
Adhesion Assay.  Adhesion of  cells fluorescently labeled with 2'7'- 
bis-(2-carboxyethyl)-5 (and -6)-carboxyfluorescein (BCECF; Mo- 
lecular Probes, Inc., Eugene, OR) to plates coated with purified 
LFA-1 was performed as previously described (7, 14, 15). Cells were 
pretreated with a 1:200 dilution of mAb ascites for 45 min at 4~ 
and 10  s cells were transferred to each well. Cell lines adhered to 
solid phase LFA-1 for 1 h at 37~  and nonadherent cells were re- 
moved by six aspirations with a 23-gauge needle. Lymphocytes and 
blasts were sedimented by centrifugation (30 g for 5 min) and in- 
cubated at 37~  for 30 min. Unbound lymphocytes and blasts were 
removed by flicking media from the plate eight times, with 100 
gl added between each wash. Flicking was more effective for thor- 
ough removal of  unbound T lymphocytes, which were more difficult 
to remove by aspiration because of their small size. Fluorescence 
was quantitated from the 96-well plates  using a Pandex fluores- 
cence concentration  analyzer  (Baxter Healthcare Corp.,  Mun- 
delein, IL). 
Results and Discussion 
To characterize the LFA-1--dependent, ICAM-I-, ICAM-2- 
independent pathway of adhesion, mAbs were raised to SKW3 
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Figure 1.  Adhesion  of cell lines (A) and lympho- 
cytes (/3) to purified  LFA-1 is accounted  for by ICAM-1, 
ICAM-2, and ICAM-3. Cells were allowed to bind 
to LFA-1--coated  microtiter wells in the presence of 
blocking mAbs specific for ICAM-1, ICAM-2, and 
ICAM-3. Site density of LFA-1 as determined by ra- 
dioimmunoassay was 1100 sites//~m  2. Control wells 
were coated without LFA-1. mAbs used were TS2/16 
(anti-CD29),  R_R.1/1 (anti-ICAM-1), CBR.-IC2/2 
(anti-ICAM-2), and CBK-IC3/1 (anti-ICAM-3). One 
of four representative  experiments  is shown, and error 
bars indicate 1 SD. 
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Figure 2.  Flow cytometric analysis of ICAM-1, ICAM-2, and ICAM-3 expression.  (A) Lymphoblastoid cell lines (A) or blood leukocytes and 3-d 
PHA activated lymphocytes (B) were labeled with saturating amounts of dtlaer mAb RR1/1 (anti-ICAM-1), mAb CBK-IC2/1 (anti-ICAM-2), mAb 
CBR-IC3/1 (anti-ICAM-3), or nonbinding control mAb X63 (thin lines),  and were followed by FITC-anti-mouse immunoglobulin. 
and were screened in combination with anti-ICAM-1 and 
anti-ICAM-2 mAbs for the ability to inhibit binding of this 
cell line to purified LFA-1. One mAb, CBR-IC3/1 (IgG1), 
was selected that completely inhibited this novel pathway of 
adhesion (Fig. 1 A). CBR-IC3/1 does not react with purified 
LFA-1 or COS cells transfected with either ICAM-1, ICAM-2, 
or LFA-1 cDNAs (data not shown), and it does react with 
the SLA cell line, which was derived from a LFA-l-deficient 
patient (16). The antigen recognized by CBR-IC3/1 is thus 
distinct from ICAM-1, ICAM-2, and LFA-1. By analogy to 
ICAM-1 and ICAM-2, whose names were based on their 
identification as ligands for LFA-1, we have designated this 
third counter-receptor ICAM-3; whether it also belongs to 
the Ig superfamily remains to be determined. 
Adhesion of SKW3 to purified LFA-1 was only slightly 
inhibited by a combination of blocking anti-ICAM-1 and anti- 
ICAM-2 mAbs. When the anti-ICAM-3 mAb, CBR-IC3/1, 
was added alone, it significantly inhibited the adhesion, and 
this inhibition was complete when combined with blocking 
anti-ICAM-2 mAb (Fig. 1 A). Thus, adhesion of SKW3 to 
purified LFA-1 was mediated largely by ICAM-3 and also, 
in part by ICAM-2. In adhering to LFA-1, each of four cell 
lines utilized the three ICAMs to different degrees, as demon- 
strated by the different patterns of mAb inhibition (Fig.  1 
A). The adhesion of the B lymphoblastoid cell line, JY, oc- 
curred through an ICAM-1 pathway with smaller contribu- 
tions through the ICAM-2 and ICAM-3 pathways;  inhibi- 
tion was partial with ICAM-1 mAb and almost complete 
when combined with either ICAM-2 or ICAM-3 mAb. An- 
other B lymphoblastoid  cell line, SLA, utilized both ICAM-1 
and ICAM-3,  since adhesion was not inhibited by either 
ICAM-1 or ICAM-3 mAb alone and almost completely by 
the two mAbs together. The thymoma cell line, Jurkat, used 
both the ICAM-2 and ICAM-3 pathways of adhesion, with 
a small contribution by ICAM-1. There is considerable redun- 
dancy in use of ICAMs since for each of these cell lines, mAbs 
to at least two ICAMs were required to achieve substantial 
inhibition. 
The pattern of distribution of ICAM-3 differed from that 
of ICAM-1 and ICAM-2 in several ways. Unlike ICAM-1 
and ICAM-2, ICAM-3 was not expressed on either resting 
or stimulated endothelium (data not shown). This finding 
agrees with the observation that LFA-1--dependent binding 
of cells to both resting and stimulated endothelium was com- 
pletely inhibited by a combination of mAbs to ICAM-1 and 
ICAM-2 (7). ICAM-3 was restricted to the hematopoietic 
lineage, being highly expressed on lymphoid and monocytic 
cell lines, with a few exceptions (Fig. 2 A and data not shown). 
In all cases examined thus far, expression  of ICAM-3 was 
coordinate with the LFA-l-dependent, ICAM-I-, ICAM-2-in- 
dependent pathway of adhesion. Cells binding LFA-1 solely 
through ICAM-1 and ICAM-2 did not express ICAM-3 (en- 
dothelium, Raji),  while cell lines that bound weakly 0-Y, 
U937, Sup T) or strongly (SKW3, Jurkat, SLA) through 
this third pathway of adhesion had correspondingly low or 
high ICAM-3 surface expression.  In all cases, the combina- 
tion of all three anti-ICAM mAbs completely eliminated 
binding to LFA-1. 
ICAM-3 differed markedly from ICAM-1 and ICAM-2 
in its expression on leukocytes (Fig. 2 B). ICAM-3 was ex- 
pressed at high levels on resting lymphocytes, monocytes, and 
neutrophils, whereas ICAM-1 and ICAM-2 were expressed 
much more weakly or were absent. Upon activation of lym- 
phocytes with PHA, ICAM-3 expression increased two- to 
threefold, whereas expression of ICAM-1 was greatly increased 
(7,  17)  (Pig.  2 B). 
We tested the functional importance of the three ICAMs 
in adhesion of T lymphocytes to LFA-1 (Fig. 1 B). Resting 
lymphocytes were previously shown to bind strongly to 
purified LFA-1 (14), and we found that this binding is al- 
most completely ICAM-3 dependent. After mitogenic acti- 
vation with PHA, however, adhesion to LFA-1 occurred chiefly 
through ICAM-1, correlating with its increased surface ex- 
pression, and in lesser degree through ICAM-3. 
The relative affinity  of the three ICAMs for LFA-1 can 
be examined by comparing their contributions to binding 
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ICAM-3. (A and B) lzSI-hbeled cell ly- 
sates were immunoprecipitated  with ti- 
ther (lanes 1) nonbinding control X63 
or (lanes 2) mAb CBR-IC3/1, and sub- 
jected to SDS-PAGE  under nonngludng 
(A)  or reducing (B)  conditions.  (C) 
mI-labded  SKW3  cell  lysates  were 
immunoprecipitatcd with either non- 
binding control mAb X63, mAb W6/ 
32  (anti-FILA-A,B,C),  mAb  R_K1/1 
(anti-ICAM-1),  mAb C~R/IC2/t (and- 
ICAM-2), or mAb CBR-IC3/1 (anti- 
ICAM-3)  and  treated  with  (+)  or 
without (-) N-glycanase  before SDS- 
PAGE.  All immunoprecipitates were 
analyzed by 7%  SDS-PAGE and sub- 
jected to autoradiograpby;  reduced mo- 
lecuhr mass standards are shown to the 
right. 
LFA-1 (Fig. 1) with their cell surface expression as measured 
by immunofluorescence flow cytometry (Fig. 2). This com- 
parison  revealed that ICAM-1  has the greatest  affinity for 
LFA-1, and that ICAM-2 and ICAM-3 have similar,  but lower, 
affinities. For instance, Jurkat cells expressed ICAM-2 and 
ICAM-3 at similar levels, and each contributed to binding 
to LFA-1. Where ICAM-2 expression was greater than that 
of ICAM-3, such as on JY ceUs, the ICAM-2 pathway of 
LFA-1 adhesion prevailed over ICAM-3. In contrast, SLA and 
SKW 3  expressed three- to  fourfold  more ICAM-3  than 
ICAM-2, and the ICAM-3 pathway of adhesion predomi- 
nated over the ICAM-2 pathway.  When ICAM-1  was ex- 
pressed  in  comparable  or  somewhat  lesser  amount  than 
ICAM-2 or ICAM-3, as was the case with SLA, JY, and the 
PHA-activated T cells, the ICAM-1 pathway of adhesion was 
dominant. 
Immunoprecipitates  of ICAM-3 from various t2SI-labeled 
cell lines revealed a band of 124,000 Mr under reducing con- 
ditions, with slightly increased mobility under nonreducing 
conditions (Fig. 3, A  and B). Treatment  with N-glycanase 
resulted in reduction of the ICAM-3 band to Mr 87,000, in- 
dicating that ICAM-3, like ICAM-1  (17, 18) and ICAM-2 
(7), is a highly glycosylated  protein (Fig. 3 C). The biochemical 
characteristics, patterns  of expression, and functional prop- 
erties of ICAM-3 distinguish it from previously described 
adhesion molecules, including the human homing receptor 
LAM-1  (19), the inducible  endothdial adhesion  molecule 
VCAM-1 (20-22),  and the VLA family of matrix receptors 
(23); no mAbs with similar cell distributions were found in 
the data bases from the third or fourth leukocyte workshop 
(24, 25). 
The existence of three LFA-1 ligands suggests specializa- 
tion for different aspects of LFA-l-dependent leukocyte in- 
teractions. ICAM-1 is basally expressed on endothdium and 
many epithelial cell types and is strongly induced in inflam- 
mation and immunity, where it is hypothesized to regulate 
ceil localization (1) and facilitates recognition of specific an- 
tigens (26, 27). Since  ICAM-2 is the predominant LFA-1 ligand 
on resting endothdium, this pathway of adhesion may have 
important consequences for normal recirculation  of LFA- 
1-bearing lymphocytes through tissue endothelium (28-31). 
The finding that adhesion of resting T lymphocytes to LFA-1 
occurs primarily via ICAM-3, combined with the fact that 
ICAM-3 is much better expressed  than the other LFA-1 ligands 
on monocytes  and resting lymphocytes,  implies an impor- 
tant role in the initiation of immune responses. Recent studies 
have shown that B lymphocyte activation stimulates avidity 
of cell surface LFA-1 (32, 33) in a manner analagous to that 
reported for T lymphocytes (14, 34). Our studies predict that 
1CAM-3 on T lymphocytes would facilitate their interaction 
with antigen-presenting B lymphocytes. Furthermore, a role 
is suggested for LFA-1 ligand(s) other than ICAM-1 in both 
allogeneic and autologous mixed lymphocyte reactions (35) 
and in lysis by T  cells of certain target cells (36). 
The existence of multiple ICAMs may also have implica- 
tion  for  therapy.  ICAM-1  mAb  is  efficacious in  vivo  in 
prolonging renal (37) and cardiac (38) allografts. ICAM-3 
mAb may be capable of inhibiting a distinctive and perhaps 
overlapping subset of immune responses in vivo, since it in- 
hibits LFA-l-dependent adhesive interactions with a distinct 
subset of cell types. 
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